BACKGROUND: The principal aim of this report was to study second primary malignant neoplasms (SMNs) in long-term survivors of pancreatic ductal adenocarcinoma (PDAC) with regard to the germline genetic background. PATIENTS AND METHODS: A total of 118 PDAC patients after a curative-intent surgery who were treated between 2006 and 2011 were analyzed. Of the 22 patients surviving for >5 years, six went on to develop SMNs. A genetic analysis of 219 hereditary cancer-predisposition and candidate genes was performed by targeted next-generation sequencing in germline DNA from 20 of these patients. RESULTS: Of all the radically resected PDAC patients, six patients went on to subsequently develop SMNs, which accounted for 27% of the long-term survivors. The median time to diagnosis of SMNs, which included two cases of rectal cancer, and one case each of prostate cancer, malignant melanoma, breast cancer, and urinary bladder cancer, was 52.5 months. At the time of analysis, none of these patients had died as a result of PDAC progression. We identified four carriers of germline pathogenic mutations in 20 analyzed long-term survivors. One carrier of the CHEK2 mutation was found among four analyzed patients who developed SMNs. Of the remaining 16 long-term PDAC survivors, 3 patients (19%) carried germline mutation(s) in the MLH1+ ATM, CHEK2, and RAD51D gene, respectively. CONCLUSION: This retrospective analysis indicates that SMNs in PDAC survivors are an important clinical problem and may be more common than has been acknowledged to be the case. In patients with good performance status, surgical therapy should be considered, as the SMNs often have a favorable prognosis.

Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Clinical and Molecular Pathology Faculty of Medicine and Dentistry Palacky University Olomouc University Hospital Olomouc Olomouc Czech Republic

Department of Oncology Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Department of Surgery 1 Faculty of Medicine and Dentistry Palacky University Olomouc University Hospital Olomouc Olomouc Czech Republic

Institute of Biochemistry and Experimental Oncology 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Grundmann RT, Meyer F. Second primary malignancy among cancer survivors - epidemiology, prognosis and clinical relevance. Zentralbl Chir. 2012;137(6):565–574. PubMed

Lovecek M, Skalicky P, Klos D, et al. Long-term survival after resections for pancreatic ductal adenocarcinoma. Single centre study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160(2):280–286. PubMed

Ng AK, Travis LB. Subsequent malignant neoplasms in cancer survivors. Cancer J. 2008;14(6):429–434. PubMed

Teepen JC, van Leeuwen FE, Tissing WJ, et al. Long-term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER study cohort: role of chemotherapy. J Clin Oncol. 2017;35(20):2288–2298. PubMed

Minni F, Casadei R, Marrano N, et al. Second tumours in patients with malignant neoplasms of the digestive apparatus. A retrospective study on 2406 cases. Ann Ital Chir. 2005;76(5):467–472. PubMed

Jacobs NL, Que FG, Miller RC, Vege SS, Farnell MB, Jatoi A. Cumulative morbidity and late mortality in long-term survivors of exocrine pancreas cancer. J Gastrointest Cancer. 2009;40(1–2):46–50. PubMed

Gerdes B, Ziegler A, Ramaswamy A, Wild A, Langer P, Bartsch DK. Multiple primaries in pancreatic cancer patients: indicator of a genetic predisposition? Int J Epidemiol. 2000;29(6):999–1003. PubMed

Riall TS, Stager VM, Nealon WH, et al. Incidence of additional primary cancers in patients with invasive intraductal papillary mucinous neoplasms and sporadic pancreatic adenocarcinomas. J Am Coll Surg. 2007;204(5):803–813. PubMed

Chen KT, Devarajan K, Hoffman JP. Morbidity among long-term survivors after pancreatoduodenectomy for pancreatic adenocarcinoma. Ann Surg Oncol. 2015;22(4):1185–1189. PubMed

Sobin LH, Gospodarowicz M, Wittekind Ch, editors. TNM Classification of Malignant Tumours. 7th ed. New York, Hoboken: Wiley-Blackwell; 2009.

Sugimura H, Caporaso NE, Shaw GL, et al. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls. Carcinogenesis. 1990;11(9):1527–1530. PubMed

Soukupova J, Zemankova P, Lhotova K, et al. Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes. PLoS One. 2018;13(4):e0195761. PubMed PMC

Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164. PubMed PMC

AIRTUM Working Group Italian cancer figures, report 2013: Multiple tumours. Epidemiol Prev. 2013;37(4–5 Suppl 1):1–152. PubMed

Cancer Incidence in the Czech Republic, UZIS, Czech Republic, 2011. [Accessed February 5, 2018]. Available from: www.uzis.cz/en/publications/cancer-incidence-2011.

Hackert T, Tjaden C, Müller S, et al. Extrapancreatic malignancies in patients with pancreatic cancer: epidemiology and clinical consequences. Pancreas. 2012;41(2):212–217. PubMed

Schnelldorfer T, Ware AL, Sarr MG, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008;247(3):456–462. PubMed

Pavlík T, Májek O, Büchler T, et al. Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000-2008. Cancer Epidemiol. 2014;38(1):28–34. PubMed

Hu C, Hart SN, Bamlet WR, et al. Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients. Cancer Epidemiol Biomarkers Prev. 2016;25(1):207–211. PubMed PMC

Yurgelun MB, Chittenden AB, Morales-Oyarvide V, et al. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med. 2018July Epub. PubMed PMC

Havranek O, Kleiblova P, Hojny J, et al. Association of germline CHEK2 gene variants with risk and prognosis of non-hodgkin lymphoma. PLoS One. 2015;10(10):e0140819. PubMed PMC

Mohelnikova-Duchonova B, Havranek O, Hlavata I, et al. CHEK2 gene alterations in the forkhead-associated domain, 1100delC and del5395 do not modify the risk of sporadic pancreatic cancer. Cancer Epidemiol. 2010;34(5):656–658. PubMed

Chaffee KG, Oberg AL, McWilliams RR, et al. Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Genet Med. 2018;20(1):119–127. PubMed PMC

Young EL, Thompson BA, Neklason DW, et al. Pancreatic cancer as a sentinel for hereditary cancer predisposition. BMC Cancer. 2018;18(1):697. PubMed PMC

Nallamilli BRR, Hegde M. Genetic testing for hereditary nonpolyposis colorectal cancer (HNPCC) CurrProtoc Hum Genet. 2017;94(1):10.12.1–10.12.23. PubMed

Eoh KJ, Kim JE, Park HS, et al. Detection of germline mutations in patients with epithelial ovarian cancer using multi-gene panels: beyond BRCA1/2. Cancer Res Treat. 2018;50(3):917–925. PubMed PMC

Improvement of the Diagnosis of Isoattenuating Pancreatic Carcinomas by Defining their Characteristics on Contrast Enhanced Computed Tomography and Endosonography with Fine-Needle Aspiration (EUS-FNA)

CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate